Neoadjuvant Pembrolizumab May Redefine Standard of Care in Locally Advanced Head and Neck Cancer

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

A new treatment for early-stage non-small cell lung cancer (NSCLC) may soon become more accessible to Canadians.Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the …

High-Risk Patients in Post-Radiation Neck Surgery

In the evolving landscape of head and neck cancer treatment, the role of salvage neck dissection (ND) after (chemo)radiotherapy remains a pivotal but complex aspect of clinical management. Recent research published in BMC Cancer sheds new light on the postoperative complications related to salvage ND for patients with head and neck squamous cell carcinoma (HNSCC), underscoring the necessity to identify patients at high risk for significant morbi…

Neoadjuvant Immunochemotherapy Shows Promise in Oral Cancer

A groundbreaking clinical trial has unveiled promising advancements in the treatment of locally advanced oral squamous cell carcinoma (OSCC), a notoriously aggressive and frequently fatal form of cancer. Researchers have combined immunotherapy with traditional chemotherapy in a neoadjuvant setting, administering this combined approach prior to surgery. The phase II trial, recently published in Nature Communications, meticulously explores not onl…

Neoadjuvant Pembrolizumab May Redefine Standard of Care in Locally Advanced Head and Neck Cancer

Douglas Adkins, MD shares key data and findings from the phase 3 KEYNOTE-689 study.

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.